Company Overview - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [4] - The company is advancing a monoclonal antibody named verekitug, which targets the receptor for thymic stromal lymphopoietin, a key cytokine involved in inflammatory responses [4] - Verekitug is currently in separate Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps, with plans to initiate development for chronic obstructive pulmonary disease [4] Industry Context - Upstream Bio will be added to the Russell 2000® index effective December 23, 2024, which is significant for its visibility and potential investment interest [1] - The Russell 2000® Index represents approximately 10% of the total market capitalization of the Russell 3000® Index and includes around 2,000 of the smallest securities based on market cap [3] - As of December 2023, approximately $10.5 trillion in assets are benchmarked against the Russell US indexes, indicating the importance of these indexes for investment managers and institutional investors [2]
Upstream Bio Announces Addition to Russell 2000® Index